Home096530 • KOSDAQ
add
Seegene Inc
Previous close
₩25,950.00
Day range
₩25,850.00 - ₩26,200.00
Year range
₩21,250.00 - ₩36,650.00
Market cap
1.35T KRW
Avg Volume
190.50K
P/E ratio
-
Dividend yield
3.09%
Primary exchange
KOSDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (KRW) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | 113.54B | 4.34% |
Operating expense | 61.51B | -1.95% |
Net income | 14.56B | 772.99% |
Net profit margin | 12.82 | 737.91% |
Earnings per share | — | — |
EBITDA | 26.99B | 17.37% |
Effective tax rate | 21.05% | — |
Balance Sheet
Total assets
Total liabilities
| (KRW) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 563.36B | 5.18% |
Total assets | 1.22T | -2.65% |
Total liabilities | 214.46B | -2.93% |
Total equity | 1.00T | — |
Shares outstanding | 46.11M | — |
Price to book | 1.20 | — |
Return on assets | 1.98% | — |
Return on capital | 2.11% | — |
Cash Flow
Net change in cash
| (KRW) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | 14.56B | 772.99% |
Cash from operations | 37.18B | -12.83% |
Cash from investing | -76.83B | -113.10% |
Cash from financing | -14.75B | 12.37% |
Net change in cash | -48.33B | -219.69% |
Free cash flow | 21.14B | -18.94% |
About
Seegene, Inc is a Korean manufacturer of in vitro diagnostic products, particularly molecular diagnostics. Its portfolio includes a range of assays and screening products for sepsis, respiratory diseases such as influenza and respiratory syncytial virus, as well as sexually transmitted infections. It was founded in 2000. In early 2020, it began developing and distributing a range of tests for SARS-CoV-2, the virus that causes COVID-19.
Along with its headquarters in Seoul, South Korea, the company has subsidiaries in the U.S., Canada, Germany, Italy, Mexico, Brazil, and the Middle East.
In September 2010, Seegene undertook a $16.6 million initial public offering to list on KOSDAQ, a trading board of Korea Exchange. Wikipedia
Founded
Sep 16, 2000
Website
Employees
215
